Tumor microenvironment is essential for tumor cell proliferation, angiogenesis, invasion and metastasis through its provision of survival signals, secretion of growth and pro-angiogenic factors, and direct adhesion molecule interactions. This review examines its importance in the induction of an angiogenic response in multiple myeloma (MM). The encouraging results of preclinical and clinical trials in which MM has been treated by targeting the tumor microenvironment are also discussed.
Introduction
In 1889, the English surgeon Stephen Paget published his 'seed and soil' explanation of the nonrandom pattern of metastasis, and was the first to suggest that interactions between tumor cells and host cells in the microenvironment are critical in regulating tumorigenesis (Paget, 1889) . Certain favored tumor cells (the 'seed'), he said, had a special affinity for the growthenhancing milieu within specific organs (the 'soil'), and hence metastasis only occurred when the 'seed' and the 'soil' were compatible.
The importance of several components of the 'soil' in regulating tumor growth has since been emphasized: (i) the extracellular matrix (ECM); (ii) stromal cells and their growth factors and inhibitors; (iii) microvessels and angiogenic factors and (iv) inflammatory cells. There is now substantial evidence that tumor growth and progression depend on the crosstalk between malignant cells and their adjacent stromal compartment.
Angiogenesis in multiple myeloma
Multiple myeloma (MM) is a B-cell neoplasm characterized by clonal expansion of malignant plasma cells in the bone marrow, where they proliferate and acquire resistance to apoptosis and eventually lead to osteolysis, renal dysfunction and anemia. It is still incurable with a median survival of approximately 4 years.
Bone marrow angiogenesis plays an important role in the pathogenesis and progression of MM, as in other hematological malignancies . Growth is halted and a dormancy state is induced in the avascular phase (such as monoclonal gammopathy of undetermined significance (MGUS) or nonactive MM) (Vacca et al., 1994) , whereas with clonal expansion and epigenetic modifications (hypoxia, shear stress) of the microenvironment tumor plasma cell subsets switch to an angiogenic phenotype that generates the 'vascular phase' (active MM), and involves changes in the local balance between pro-and antiangiogenic factors ( Table 1) .
The cause of induction of the vascular phase is the subject of current investigation (Vacca and Ribatti, 2006) . Several studies show overexpression and secretion of vascular endothelial growth factor (VEGF) by the clonal plasma cells (Ria et al., 2003) . Vascular endothelial growth factor stimulates proliferation and chemotaxis in both endothelial cells (EC) via VEGF receptor-2 (VEGFR-2) and stromal cells via VEGFR-1. These cells are rapidly phosphorylated by the interaction with VEGF, and signal via extracellular signal-related kinase-2 (Vacca et al., 2003b) .
A murine model for MM indicates that the switch is preceded by the expression of mRNA for VEGF and secretion of the protein by plasma cells, and by a shift from CD45-positive to CD45-negative plasma cells that are the VEGF producers . Accordingly, CD45 expression (as the CD45-positive percentage) by a patient's bone marrow plasma cells is inversely correlated with the degree of bone marrow angiogenesis (Kumar et al., 2005) . Other studies demonstrate that the expression levels of VEGF, fibroblast growth factor-2 (FGF-2) and their receptors overlap between MGUS, smoldering MM (SMM) and newly diagnosed MM (NMM). However, 63% of MGUS samples inhibit angiogenesis in vitro compared to 43% SMM and 4% NMM. Hence, the angiogenic switch from MGUS to NMM is partly refefable to an increasing tumor burden rather than increased expression of VEGF and/or FGF-2 and by a loss of the MGUS antiangiogenic activity (Kumar et al., 2004) .
Angiogenic-related genes in multiple myeloma
Gene expression profiling of patients with MM and MGUS has revealed well-defined mRNA expression patterns (De Vos et al., 2002; Zhan et al., 2002; Davies et al., 2003) . However, while MGUS and MM plasma cells can be distinguished from normal plasma cells, they are difficult to differentiate from each other. This suggests that changes in the bone marrow microenvironment rather than a genetic change in the plasma cells account for the malignant changeover.
Increased levels of expression of interleukin-8 (IL-8), angiopoietin-1 (Ang-1) and insulin-like growth factor-1 (IGF-1) transcripts (but not of interleukin-6 (IL-6) and VEGF) have been observed in MM plasma cells vs healthy plasma cells (Munshi et al., 2004) , while Vacca et al. (2005) have used the DNA microarray and RT-PCR to show an overall induction of VEGF, FGF-2, hepatocyte growth factor-scatter factor (HGF-SF), IGF-1 and IGF binding protein 3 (IGFBP-3) genes in the EC of MM (MMEC) and MGUS (MGUSEC) patients compared to healthy human umbilical vein EC (HUVEC).
Multiple myeloma microenvironment
Since MM mainly progresses in the bone marrow, signals from this microenvironment play a critical role in maintaining plasma cell growth, migration and survival. The pathogenesis of most cancers includes complex and mutual interactions that affect the number and phenotype of the tumor cells and host stromal cells (Allinen et al., 2004) . Reciprocal positive and negative interactions between plasma cells and bone marrow stromal cells (BMSC), namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, chondroclasts, EC, EC progenitor cells, T lymphocytes, macrophages and mast cells, are mediated by an array of cytokines, receptors and adhesion molecules. The MM microenvironment is formed by clonal plasma cells, ECM proteins and BMSC, which are intimately involved in all biological stages of intramedullary growth (Table 2) (Kuehl and Bersagel, 2002) . Interactions between these components determine the proliferation, migration and survival of plasma cells, as well as their acquisition of drug resistance and the development of diseases (Damiano et al., 1999; Hazlehurst et al., 2000 Hazlehurst et al., , 2003 . Receptors expressed by plasma cells, such as a V b3 integrin, are crucial for their relationships with each other (homotypic interrelationships) and with ECM proteins (Vacca et al., 2001) . Very late activating antigen-4 (VLA-4), leukocyte function-associated antigen (LFA-1), mucin-1 antigen expressed by plasma cells, and vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) expressed by BMSC mediate their heterotypic and homotypic interactions. All these interactions result in enhanced expression and release of cytokines and growth factors needed for the plasma cell survival (Hideshima et al., 2005) (Figure 1 ).
Plasma cells in the bone marrow microenvironment secrete cytokines, such as tumor necrosis factor-alpha (TNF-a) (Hideshima et al., 2001c) , transforming growth factor-beta (TGF-b) , VEGF (Dankbar et al., 2000) , FGF-2 , HGF-SF (Borset et al., 1996a) , Ang-1 (Giuliani et al., 2002) and matrix metalloproteinases (MMPs) (Barilleé t al., 1997; Vacca et al., 1999) . Moreover, binding of plasma cells to BMSC triggers transcription and secretion by the latter of cytokines, such as IL-6 (Dankbar et al., 2000) , IGF-1 (Ferlin et al., 2000) and VEGF (Gupta et al., 2001) and CXCL12/stromal cellderived factor-1a (SDF-1a) (Pellegrino et al., 2005) , that mediate cell growth (IL-6, IGF-1, VEGF), survival (IL-6, IGF-1), drug resistance (IL-6, IGF-1, VEGF), migration (IGF-1, VEGF, MMPs, SDF-1a) and angiogenesis (VEGF) in the bone marrow. Endothelial cell of MM differ from HUVEC. They produce growth and invasive factors for plasma cells, including VEGF, FGF-2, MMP-2 and MMP-9 (Vacca et al., 2003a). Bone marrow MMEC express more mRNA and secrete larger amounts of the CXC chemokines CXCL8/ IL-8, CXCL11/interferon-inducible T-cell alpha chemoattractant, CXCL12/SDF-1a and CCL2/monocyte chemotactic protein-1 (MCP-1) than HUVEC, and paired plasma cells express cognate receptors to a variable extents, which suggests that paracrine loops between MMEC and plasma cells involving CXC chemokines and their receptors are operative in MM patients and mediate plasma cell proliferation and chemotaxis (Pellegrino et al., 2004) .
This tumor-host interplay highlights a reciprocal relationship that sustains and promotes the progression of MM by inducing pathological developments, such as angiogenesis and osteolysis (Kuehl and Bersagel, 2002) .
Angiogenic cytokines

Interleukin-6
Interleukin-6 is a major growth and survival factor for MM plasma cells. It is mainly produced by BMSC and also by plasma cells themselves. It is angiogenic (Motro et al., 1990) . Contact of plasma cells with BMSC upregulates the latter's transcription and secretion of IL-6 which are further enhanced by cytokines (particularly TGF-b) secreted by plasma cells . Interleukin-6 stimulates VEGF secretion via an IL-6 receptor expressed by plasma cells (Cohen et al., 1996; Bellamy et al., 1999; Dankbar et al., 2000; Gupta et al., 2001) . Thus, IL-6 is angiogenic both directly and indirectly via VEGF.
Vascular endothelial growth factor
The secreted isoforms of VEGF (also called VEGF-A), such as VEGF 121 , VEGF 145 and VEGF 165 , as well as the ECM-and surface-bound VEGF 189 and VEGF 206 are produced by both MM cell lines and a patient's bone marrow plasma cells (Bellamy et al., 1999; Podar et al., 2001) .
Vascular endothelial growth factor acts as an autocrine inducer of growth and chemotaxis via VEGFR-1 . It increases IL-6 production by BMSC via VEGFR-2 and thus forming a paracrine loop for tumor growth (Dankbar et al., 2000) and angiogenesis. Moreover, adhesion of plasma cells to BMSC increases VEGF secretion by both cell types (Hideshima et al., 2005) , and so enhances angiogenesis. Vascular endothelial growth factor production by plasma cells is also regulated by TNF-a of BMSC (Neufeld et al., 1999) .
Vascular endothelial growth factor-A and its major receptor VEGFR-2 are highly expressed by bone marrow MMEC at both mRNA and protein levels compared to MGUSEC . Proliferation and capillarogenesis of MMEC are prevented by a neutralizing anti-VEGF antibody, and more efficacioulsy by an anti-VEGFR-2 antibody. These data suggest the existence of an autocrine loop of VEGF in MMEC. Vincent et al. (2005) have shown that VEGF released by fetal BMSC interacts with VEGFR-1 of MM plasma cells in a paracrine fashion. Moreover, a neutralizing anti-VEGFR-1 monoclonal antibody sizeably, but only partially, blocks plasma cell motility in vitro, indicating that the functional VEGF-A/VEGFR-1 interaction is essential for MM homing and migration, and that BMSC secrete other cytokines and/or chemokines that promote plasma cell migration irrespective of the VEGF-A/VEGFR-1 signaling. Vascular endothelial growth factor may also mimic the role of macrophage colony stimulating factor (M-CSF) by increasing osteoclast development (Niida et al., 1999) and stimulating resorptive activity (Nakagawa et al., 2000) , so that bone destruction is mediated via more than one route.
Vascular endothelial growth factor triggers a signaling cascade in plasma cells, including the ERK pathway, which mediates cell growth, and the phosphatidylinositol-3 kinase/protein kinase C (PKC)-dependent cascade that mediates migration . Le Gouill et al. (2004) have demonstrated that VEGF upregulates expression of antiapoptotic proteins, including myeloid cell leukemia, survivin, and cellular inhibitor of apoptosis protein. Furthermore, free bovine serum (starvation)-induced apoptosis in plasma cells is partially prevented by VEGF, confirming that this is a potent antiapoptotic cytokine in MM (Lichtenstein et al., 1995 , Chauhan et al., 1997a Tu et al., 2000) .
BMSC secrete other VEGF-A homologues, namely VEGF-C and VEGF-D (Vacca et al., 2003b) . Vascular endothelial growth factor-A is thus prevalently produced by plasma cells and stimulates the proliferation and chemotaxis of MMEC (i.e., angiogenesis) via VEGFR-2 and of BMSC via VEGFR-1. Activation of the latter results in VEGF-C and VEGF-D production that stimulates plasma cell growth via VEGFR-3.
Fibroblast growth factor-2 Plasma cells are the prevailing source of FGF-2 in the bone marrow of patients with active MM Bisping et al., 2003) . This explains why FGF-2 concentrations in marrow aspirates and peripheral blood correlate with MM activity (Di Raimondo et al., 2000; Sezer et al., 2001; Sato et al., 2002) . Bisping et al. (2003) have illustrated the expression of highaffinity FGFR-1 through R-4 in RPMI-8226 and U266 MM cell lines and patients' plasma cells, as well as in BMSC, and hence the likelihood of both autocrine and paracrine loops of growth and angiogenesis. Moreover, they demonstrated that FGF-2 induces a time-and dose-dependent increase in IL-6 secretion by BMSC, in the absence of vessels, indicating that its paracrine effects of FGF-2 do not depend on the presence of microvascular EC in the vicinity of plasma cells. These findings suggest that FGF-2 is both an angiogenic growth factor in MM via IL-6 and a supporter of plasma cell growth and survival by paracrine stimulation of the IL-6 released by BMSC. Plasma cell FGF-2 is also a direct angiogenic factor .
Tumor necrosis factor-alpha Tumor necrosis factor-alpha mediates upregulation of adhesion molecules of plasma cells (LFA-1 and VLA-4) and BMSC (ICAM-1 and VCAM-1), and thus enhances heterotypic adhesions and activates IL-6 secretion by BMSC (Hideshima et al., 2001a) .
Tumor necrosis factor-alpha secreted by plasma cells induces NF-kappa B-dependent upregulation of adhesion molecules on both MM and BMSC (CD49d, CD54) (Hideshima et al., 2001c) , thereby increasing the binding of MM to BMSC with associated cell adhesion mediated-drug resistance and induction of IL-6, IGF-1 and VEGF secretion by BMSC Hideshima et al., 2001a Hideshima et al., , 2002b .
Activation of plasma cells via CD40 ligand, a TNF-a family member, induces VEGF secretion in BMSC, which mediates MM cell homing and migration, as well as angiogenesis .
Hepatocyte growth factor-scatter factor and syndecan-1 Hepatocyte growth factor-scatter factor is a pleiotropic cytokine that induces complex biological responses in target cells, including motility, growth and morphogenesis. All its known biological effects are transduced via the transmembrane tyrosine kinase Met. Signals are amplified by syndecan-1 (CD138) which binds HGF-SF and acts as its functional co-receptor (Derksen et al., 2002) . Syndecan-1 regulates tumor cell growth and survival, and its elevated serum levels correlate with increased tumor cell mass, MMP-9 activity, and poor prognosis (Dhodapkar et al., 1998; Kaushal et al., 1999) .
Multiple myeloma cell lines and bone marrow plasma cells express HGF-SF and its receptor c-Met, and circulating HGF-SF levels are of prognostic significance in MM (Borset et al., 1996a, b; Seidel et al., 1998) . Derksen et al. (2003) showed that Met is expressed by the majority of MM cells, and that HGF-SF is a potent MM growth factor which stimulates the proliferation of plasma cells and protects them from apotosis. Hepatocyte growth factor-scatter factor stimulation of plasma cells triggers signaling routes involved in regulation of their cell proliferation and survival. The positive correlation observed by Andersen et al. (2005) between HGF-SF and syndecan-1 and bone marrow angiogenesis shows that the former contribute to the induction of marrow angiogenesis in MM patients.
Angiopoietin-1
Human MM cell lines express and secrete Ang-1, but not its antagonist Ang-2 (Giuliani et al., 2002) . Ang-1 alone is expressed in about 47% of newly diagnosed MM patients in stages I-III. Moreover, microarray comparison of the gene expression profiles of bone marrow plasma cells and extramedullary plasmacytoma cells has shown an eightfold upregulation of Ang-1 expression in the latter (Hedvat et al., 2003) .
Evaluation of the density and number of vessels per field in bone biopsies has revealed a significant increase of angiogenesis in Ang-1 positive as opposed to Ang-1-negative patients (Giuliani et al., 2002) . Microarray comparison of Ang-1 expression in plasma cells vs healthy twin plasma cells has produced similar results. A 5.8-fold increase of Ang-1 transcript was detected in MM associated with higher angiogenesis (Munshi et al., 2004) . The presence of anti-Tie2 (Ang-1 receptor) blocking antibody completely abolished vessel formation induced by conditioned medium of several human MM cell lines (Giuliani et al., 2002) .
Multiple myeloma plasma cells influence the expression of Angs and Tie2 receptor in the bone marrow milieu. Several human MM cell lines upregulate the expression of Tie2 by EC at both the mRNA and the protein level (Giuliani et al., 2002) . This in vitro effect has been confirmed in vivo by the finding of overexpression of Tie2 in isolated bone marrow MMEC as compared to HUVEC (Vacca et al., 2003a) . Nakayama et al. (2004) showed that mast cells promote the growth of plasma cell tumors through secretion of Ang-1, which stimulates angiogenesis in conjunction with tumor-derived VEGF.
Matrix metalloproteinases
Matrix metalloproteinase production in vivo and in vitro is increased by angiogenic agents (Coussens and Webb, 1996) . In cancer, MMP activity is thought to be an integral part of both generalized tissue remodeling and angiogenesis (Johnson et al., 1998) . Matrix metalloproteinases degrade many components of the ECM and hence promote invasion, metastasis and angiogenesis. During degradation of the ECM, matrix-bound growth factors and angiogenic factors are released. Under physiological conditions the activity of MMPs is tightly controlled by their endogenous tissue inhibitors (TIMP). Vacca et al. (1999) focused on the invasive potential of bone marrow plasma cells during MM progression. They found by in situ hybridization that plasma cells of MGUS and MM patients express MMP-2 and -9 mRNA. The MMP-2 mRNA-related signal was stronger in patients with active MM than in those with nonactive MM and MGUS. The MMP-9 mRNArelated signal was lower than that of MMP-2 in all patient groups and overlapped between them. Since MMP-2 degrades the major components of the ECM contained in the subendothelial basement membrane, these findings suggest that plasma cells of active MM patients are especially capable of invading the membrane and entering the circulation.
Since the bone marrow stromal microenvironment is involved in the development of MM, investigation of MMPs production in BMSC is an important issue. BMSC secrete MMP-1 and MMP-2 (Barille´et al., 1997). Matrix metalloproteinase-1 production by BMSC is upregulated in response to MM cells, while MMP-9 production is slightly increased in co-cultures (Barilleé (CatlettFalcone et al., 1999; Jourdan et al., 2003) . Plasma cells become independent of the IL-6/JAK2/STAT3 pathway when co-cultured with BMSC. This emphasizes that the crosstalk between plasma cells and BMSC stimulates additional IL-6-independent pathways. In fact, also IL-6 triggers plasma cells proliferation also via the Ras/Raf/ MEK/MAPK cascade and protects against dexamethasone (dex)-induced apoptosis by Pl3K/AKT signaling (Ogata et al., 1997; Tu et al., 2000; Hideshima et al., 2001a; Hu et al., 2003) .
Mcl-1 is tightly regulated by IL-6. It is essential for the survival of plasma cells in vitro (Zhang et al., 2002) , and overexpressed by those from patients with relapse or poor prognosis (Wuillelme-Toumi et al., 2005) .
Insulin-like growth factor-1 induces proliferation, survival and drug resistance of plasma cells via Ras/ MAPK and Pl3K/AKT signaling cascades; it is a more potent inducer of AKT signaling and NF-kB activation than IL-6, and confers protection against dex-mediated apoptosis (Tu et al., 2000; Qiang et al., 2002) . Insulinlike growth factor-1 also attenuates the anti-MM activity of other antitumor drugs, including cytotoxic chemotherapy and proteasome inhibitors .
Vascular endothelial growth factor induces modest proliferation and pronounced migration via MEL/ MAPK and Pl3K/PKC signaling pathways, respectively ), but not with ERK activation . It is abrogated by neutralizing specific antibody, but not by MAPK inhibitors. Le Gouill et al., (2004) showed that VEGF upregulates Mcl-1 expression in MM cell lines and MM plasma cells; conversely, a pan-VEGF inhibitor inhibits VEGFinduced upregulation of Mcl-1 associated with decreased proliferation and induction of apoptosis ).
Stromal cell-derived factor-1 promotes proliferation, induces migration and protects against dex-induced apoptosis via activation of the MAPK, Pl3K/AKT, and NF-kB signaling cascades, respectively (Hideshima et al., 2002b) .
How the cytokines work together to an increased angiogenesis in multiple myeloma?
Vascular endothelial growth factor augments IL-6 secretion by BMSC, and IL-6 augments VEGF secretion by plasma cells (Dankbar et al., 2000) . Transforming growth factor-beta is secreted by plasma cells and triggers IL-6 production by BMSC , further enhancing paracrine plasma cell growth and angiogenesis. Most IL-6 is secreted by BMSC and its transcription and secretion are further enhanced by secretion of TGF-b, TNF-a, VEGF and IL-1 within the bone marrow microenvironment Costes et al., 1998; Dankbar et al., 2000; Gupta et al., 2001; Hideshima et al., 2001b) . Tumor necrosis factor-alpha is a more potent stimulus of IL-6 secretion in BMSC than VEGF or TGF-b (Hideshima et al., 2001b) .
Stimulation of BMSC with FGF-2 induces a timeand dose-dependent increase in IL-6 secretion; conversely, stimulation with IL-6 enhances FGF-2 expression and secretion by MM cell lines as well as patients' plasma cells (Bisping et al., 2003) . This finding suggests a paracrine interaction of IL-6 and FGF-2 between plasma cells and BMSC that triggers both angiogenesis and plasma cell growth and survival (Chesi et al., 2001) .
How the pro-angiogenic activity of the cytokines may be counteracted?
Since the cytokine network between plasma cells and BMSC in the bone marrow milieu promotes plasma cell growth, survival and migration, and plasma cells in the bone marrow are resistant to conventional agent treatment, targeting this network constitute a rationale to the treatment of MM (Figure 2) .
Inhibition of NF-kB activity by specific IKK inhibitor downregulates IL-6 secretion in BMSC and related plasma cell growth (Hideshima et al., 2002a) . Furthermore, inhibition of either p38MAPK or TFG-b by specific inhibitors downregulates IL-6 secretion in BMSC Hideshima et al., 2004) . Targeting inhibition of Ras/Raf/MEK/ERK signaling by using the farnesyltransferase inhibitors SCH66336 and R115777 abrogates plasma cell growth (Ochiai et al., 2003) . The proteasome inhibitor bortezomib (formerly PS-341) can overcome the protective effect of IL-6 against dex-induced apoptosis in MM by inducing caspase-8/-9/-3 activation, which results in caspase-dependent gp130 cleavage (Hideshima et al., 2001b (Hideshima et al., , 2003b . Moreover, bortezomib inhibits DNA repair and may restore the sensitivity of MM cells to DNA-damaging chemotherapeutic agents, suggesting that its combination with conventional chemotherapy may augment clinical effectiveness and overcome resistance in patients with relapsed or refractory MM .
Vascular endothelial growth factor and VEGFR inhibitors may offer therapeutic promise. Thalidomide directly inhibits the growth and survival of MM cells and/or BMSC, modulates adhesive interactions between Figure 2 Intercellular interactions between plasma cells and stromal cells in multiple myeloma. The pathways to block both cell populations in terms of receptors, growth factors and intracellular signaling proteins, are circled. them, and alters the secretion and bioactivity of cytokines they release into the bone marrow milieu (Ribatti and Vacca, 2005) . Treatment with two classes of thalidomide analogs, namely selected cytokine inhibitory drugs and immunomodulatory drugs, may alter MM adhesion to BMSC and fibronectin, and abrogate the upregulation of IL-6 and VEGF induced by tumor cell binding. Ongoing studies are evaluating the efficacy of a humanized monoclonal antibody against VEGF, bevacizumab (Avastatin) in patients with relapsed or refractory MM (with or without thalidomide) (Podar and Anderson, 2005) .
PTK 787/ZK222584 is an oral tyrosine-kinase inhibitor that also binds VEGFR-1. Hence, it acts directly on MM plasma cells and inhibits the autocrine VEGF/ VEGFR-1-induced plasma cell growth and migration and the paracrine (IL-6 mediated) growth . PTK/ZK (1.25 mg/day) is currently being evaluated in clinical phase I trials (Bruno et al., 2005) . Indazolypyrimidine GW654652 inhibits all three VEGF receptors with similar potency and the VEGF-triggered migration activity and proliferation of MM cell lines, including those sensitive and resistant to conventional therapy . GW654652 also acts in the bone marrow milieu, since it inhibits both IL-6 and VEGF secretion, as well as proliferation of plasma cells induced by their binding to BMSC; it is antiangiogenic too since blocks HUVEC proliferation .
The therapeutic action of bortezomib-induced inhibition of the proteasome in MM is probably a result of direct cytotoxicity and effects on the bone marrow milieu (Hideshima et al., 2003b) . The antiangiogenic effect of bortezomib is another potential mechanism of its anti-MM activity (Le Blanc et al., 2002; Roccaro et al., 2006) . Moreover, bortezomib downregulates caveolin-1 expression and inhibits caveolin-1 tyrosine phosphorylation, which are required for VEGFmediated MM cell migration on fibronectin, and blocks VEGF-induced tyrosine phosphorylation of caveolin-1 in HUVEC, thereby inhibiting ERK-dependent EC proliferation (Podar and Anderson, 2005) .
High local VEGF concentration in the MM bone marrow milieu suppresses the antiproliferative effect of several chemotherapeutic agents, hence promoting multidrug resistance (Tran et al., 2002) . Combination of these agents along with drugs that block VEGF signaling may enhance anti-MM efficacy by normalizing and sensitizing the tumor vasculature and improving oxygenation and delivery of such agents to tumor cells and EC.
Inhibition of wild-type and constitutively activated FGFR-3 autophosphorylation in human MM cell lines by the FGFR-specific tyrosine kinase inhibitors SU5402, SU10991, PD173074 or CHIR258 is associated with decreased viability and tumor cell growth arrest, both in vitro and in vivo in a murine model (Grand et al., 2004; Trudel et al., 2004 Trudel et al., , 2005 .
Insulin-like growth factor-1 receptor (IGF-1R) inhibition whether by neutralizing anti-IGF-1R-specific monoclonal antibodies, antagonistic peptides, or selective IGF-1R kinase inhibitors prevents MM cell proliferation by blocking the Ras/Raf/MAPK and Pl3K/AKT-1 pathways; induces phosphorylation of proapoptotic FKHR; downregulates intracellular antiapoptotic proteins, and also increases telomerase activity (Ferlin et al., 2000; Gen and Rudikoff, 2000; Tu et al., 2000; Akiyama et al., 2002; Mitsiades et al., 2002; Qiang et al., 2002) .
Inflammatory cells
Tumor cells are surrounded by an infiltrate of inflammatory cells: lymphocytes, neutrophils, macrophages and mast cells, which communicate via a complex network of intercellular signaling pathways, mediated by surface adhesion molecules, cytokines and their receptors. This infiltrate, particularly macrophages, may contribute to tumor angiogenesis, and there are many reports of associations between macrophage infiltration, vascularity and prognosis. Tumor-associated macrophages accumulate in poorly vascularized hypoxic or necrotic areas (Leek et al., 1999) , and respond to experimental hypoxia by increasing the release of VEGF and FGF-2 and a broad range of other factors, such as TNF-a, urokinase and MMPs (Bingle et al., 2002) . Moreover, activated macrophages synthesize and release inducible nitric oxide synthase, which increases blood flow and promotes angiogenesis (Jenkins et al., 1995) . Lastly, the angiogenic factors secreted by macrophages stimulate mast cell migration (Gruber et al., 1995) .
Chemokines, such as macrophage inflammatory protein-1 (MIP-1), SDF-1, and MCP-1 also have a role; some CXC chemokines, such as IL-8, are proangiogenic (Bernardini et al., 2003) . They regulate angiogenesis directly or as a consequence of leukocyte infiltration and/or induction of growth factor expression. Stromal cell-derived factor-1a upregulates secretion of IL-6 and VEGF in MM BMSC (Hideshima et al., 2002a) .
The most aggressive human cancers, namely malignant melanoma, breast carcinoma, and colorectal adenocarcinoma, are associated with a dramatic host response composed of various inflammatory cells, especially mast cells, at the tumor periphery . Mast cells infiltrate hyperplasias, dysplasias and the invasive fronts of carcinomas, where they degranulate in close apposition to EC and epithelial basement membranes.
Bone marrow angiogenesis, evaluated as microvessel area, and mast cell counts are highly correlated in patients with nonactive and active MM and in those with MGUS. Both parameters increase simultaneously in active MM . Mast cell rest near or around blood or lymphatic capillaries. Their ultrastructural picture includes a typical semilunar aspect or piecemeal degranulation of their secretory granules, unlike the immunoglobulin E-mediated massive degranulation that occurs during immediate hypersensitivity reactions (Crivellato et al., 2002 (Crivellato et al., , 2003 . This morphology is typical of the slow degranulation that takes place in delayed hypersensitivity reactions and chronic inflammation . Semilunarity may reflect a slow, but progressive release of angiogenic factors favoring chronic and progressive stimulation of mast cell degranulation.
Endothelial cells progenitor cells
Endothelial cells progenitor cells (EPC) have been isolated from circulating CD34
þ VEGFRÀ2 þ CD133 þ cells, which may home to site of neovascularization and differentiate into EC. They can participate in vasculogenesis in ischemic tissues, as well as in the maintenance of vascular homeostasis (Khakoo and Finkel, 2005) . Emerging evidence indicate that bone marrow-derived circulating EPC can contribute to tumor angiogenesis and growth of certain tumors (Ribatti, 2004) . A higher number of EPC has been demonstrated in the bone marrow of patients with active MM than in those with treated MM or with MGUS or in subjects with normal marrow (Dominici et al., 2001) , which reflects the increased angiogenic potential in MM. Zhang et al., 2005 have assessed the view that EPC level and function are correlated with MM activity. Data from 31 patients showed that their peripheral blood levels are higher in patients than in healthy controls. Vascular endothelial growth factor receptor-2 (as mRNA and protein) of EPC was also found to be higher in patients with MM than in healthy subjects, which suggests that it plays a critical role in the emergence and mobilization of EPC in MM.
Frequency of EPC was responsive to effective treatment with thalidomide and positively correlated with levels of serum M protein and b2-microglobulin, which are indicators of MM activity (Zhang et al., 2005) . Thalidomide and CC-5013 regulated the expression of Ser/thr kinase TGFbR-1, which in cooperation with HIF-1a stimulates VEGF gene expression induced by hypoxia, which in turn promotes angiogenesis (Zhang et al., 2003) . Circulating EPC can thus be envisaged as a potential target in MM and an accessible biomarker of its status.
Concluding remarks
Bone marrow microenviroment is strictly involved in the evolution of MM. Direct and indirect forms of interactions between MM cells and bone marrow stroma regulate growth, survival, homing and drug resistance of MM cells. These interactions also paly a critical role in angiogenesis.
Multiple myeloma remains an incurable malignancy, despite conventional and high-dose treatments, and new biologically based treatment approaches are needed. Novel therapeutic agents targeting not only the myeloma cells, but also the interaction between MM cells and their microenvironment, may both enhance understanding of pathogenesis of MM and provide the framework for identification and validation of other agents.
